In addition, since few immune- and peptide-based approaches have been tested in combination with IMiDs and PIs in MM patients, extensive efforts are underway to identify additive (or even synergistic) benefits when combined CD138-based treatments with these drugs and non-overlapping toxicity profiles that could enable tolerable and novel combination therapies. This evidence concerns the gene SDC1 and Miyoshi myopathy.